{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:16:00Z","timestamp":1789010160219,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clml.2018.01.001","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T13:46:47Z","timestamp":1515073607000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Marcus P.","family":"Watkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.01.001_bib1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin's disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2018.01.001_bib2","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","article-title":"Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib3","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.01.001_bib4","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib5","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.01.001_bib6","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"RAPID trial: results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.01.001_bib7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early-stage Hodgkin's lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.01.001_bib8","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib9","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib10","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/annonc\/mdl397","article-title":"ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors","volume":"18","author":"Boleti","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2007.06598.x","article-title":"G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis","volume":"137","author":"Evens","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.01.001_bib13","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2017-05-784678","article-title":"Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma","volume":"130","author":"Connors","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A\u00a0retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib15","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.14236","article-title":"Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning","volume":"179","author":"Nguyen","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.01.001_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V126.23.579.579","article-title":"Advanced stage classical Hodgkin lymphoma patients with a negative PET-scan following treatment with ABVD have excellent outcomes without the need for consolidative radiotherapy regardless of disease bulk at presentation","volume":"126","author":"Savage","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib18","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2010.08485.x","article-title":"Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses","volume":"152","author":"Gallamini","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.01.001_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","article-title":"CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy","volume":"85","author":"Falini","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease","volume":"68","author":"Durkop","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.clml.2018.01.001_bib22","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.4049\/jimmunol.172.4.2186","article-title":"Anti-CD30 antibody treatment in\u00a0vitro apoptosis in human eosinophils by extremely rapid and intense induction of extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in\u00a0vitro","volume":"172","author":"Fukuda","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2018.01.001_bib23","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib24","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib25","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib26","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.01.001_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib28","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2018.01.001_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hon.2437_68","article-title":"Results of a phase II study of brentuximab vedotin in the first line treatment of Hodgkin lymphoma patients considered unsuitable for standard chemotherapy (BREVITY)","volume":"35","author":"Gibb","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib30","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged\u00a0\u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2018.01.001_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/hon.2438_28","article-title":"Brentuximab-vedotin and bendamustine is a feasible and effective drug combination as first-line treatment of Hodgkin lymphoma in the elderly (HALO trial)","volume":"35","author":"Gallamini","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib32","doi-asserted-by":"crossref","unstructured":"Evens AM, Advani RH, Fanale MA, et\u00a0al. Sequential brentuximab vedotin (BV) before and after Adriamycin, vinblastine, and dacarbazine (BV-AVD) for older patients with untreated classical Hodgkin Lymphoma (cHL): final results from a multicenter phase II study. Presented at the 59th Annual Meeting of the American Society of Hematology, 2017; abstract\u00a0733.","DOI":"10.1182\/blood.V130.Suppl_1.733.733"},{"key":"10.1016\/j.clml.2018.01.001_bib33","doi-asserted-by":"crossref","unstructured":"J. Connors, W. Jurczak, D. Straus, et al., Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma, N Engl J Med 2017, doi:10.1056\/NEJMoa1708984, [Epub ahead of print].","DOI":"10.1056\/NEJMoa1708984"},{"key":"10.1016\/j.clml.2018.01.001_bib34","unstructured":"Connors JM, Jurczak W, Straus DJ, et\u00a0al. Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): the phase 3 Echel. Presented at the 59th Annual Meeting of the American Society of Hematology, 2017; abstract\u00a06."},{"key":"10.1016\/j.clml.2018.01.001_bib35","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib37","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2018.01.001_bib38","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.V128.22.1834.1834","article-title":"Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (Rel\/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I\/II trial","volume":"128","author":"Cassaday","year":"2016","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2018.01.001_bib39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/hon.2440_6","article-title":"Phase I\/II study of brentuximab vedotin in refractory\/relapsed Hodgkin lymphoma patients treated by chemotherapy (ICE) in second line before autologous transplantation","volume":"35","author":"Stamatoullas","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib40","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma","volume":"126","author":"LaCasce","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib41","doi-asserted-by":"crossref","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, et\u00a0al. Results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Presented at the 59th Annual Meeting of the American Society of Hematology, 2017; abstract\u00a0649.","DOI":"10.1182\/blood.V130.Suppl_1.649.649"},{"key":"10.1016\/j.clml.2018.01.001_bib42","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib43","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.01.001_bib45","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clml.2018.01.001_bib46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hon.2437_124","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow-up of the phase 2 Checkmate 205 trial","volume":"35","author":"Fanale","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib47","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib48","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib50","doi-asserted-by":"crossref","unstructured":"Ramchandren R, Fanale MA, Rueda A, et\u00a0al. Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 study. Presented at the 59th Annual Meeting of the American Society of Hematology, 2017; abstract\u00a0651.","DOI":"10.1182\/blood.V130.Suppl_1.651.651"},{"key":"10.1016\/j.clml.2018.01.001_bib51","doi-asserted-by":"crossref","unstructured":"Cohen JB, Engert A, Ansell SM, et\u00a0al. Nivolumab treatment beyond investigator-assessed progression: outcomes in patients with relapsed\/refractory classical Hodgkin lymphoma from the phase 2 Checkmate 205 study. Presented at the 59th Annual Meeting of the American Society of Hematology, 2017; abstract\u00a0650.","DOI":"10.1182\/blood.V130.Suppl_1.650.650"},{"key":"10.1016\/j.clml.2018.01.001_bib52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.seminoncol.2017.06.007","article-title":"Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","volume":"44","author":"Prasad","year":"2017","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib53","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3324\/haematol.2016.142406","article-title":"ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma","volume":"101","author":"Batlevi","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.01.001_bib54","first-page":"1","article-title":"Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma","author":"Hu","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.01.001_bib55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clml.2017.05.008","article-title":"A\u00a0phase I\/II trial of panobinostat in combination with lenalidomide in patients with relapsed or refractory Hodgkin lymphoma","volume":"17","author":"Maly","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.01.001_bib56","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/10428194.2011.608448","article-title":"A\u00a0phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517","volume":"53","author":"Kirschbaum","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.01.001_bib57","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1200\/jco.2012.30.15_suppl.8028","article-title":"Everolimus (EVE) for relapsed\/refractory classical Hodgkin lymphoma (cHL): open-label, single-arm, phase II study","volume":"30","author":"Johnston","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib58","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.01.001_bib59","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/annonc\/mdx028","article-title":"Phase II study of idelalisib, a selective inhibitor of PI3K\u03b4, for relapsed\/refractory classical Hodgkin lymphoma","volume":"28","author":"Gopal","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib60","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A\u00a0phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib61","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A\u00a0phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4160.4160","article-title":"A\u00a0Lysa phase II study of oral JAK1\/2 inhibitor ruxolitinib in advanced relapsed\/refractory (R\/R) Hodgkin lymphoma (HL)","volume":"128","author":"Van Den Neste","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib63","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3052.3052","article-title":"Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma","volume":"112","author":"Kuruvilla","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2141.2009.07963.x","article-title":"Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma","volume":"148","author":"B\u00f6lll","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.01.001_bib66","article-title":"A\u00a0phase 2 multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"114","author":"Fehniger","year":"2012","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2018.01.001_bib67","doi-asserted-by":"crossref","first-page":"8566","DOI":"10.1200\/jco.2014.32.15_suppl.8566","article-title":"A\u00a0phase 1\/2 study of lenalidomide and bendamustine (LEBEN) in chemorefractory Hodgkin lymphoma","volume":"32","author":"Corazzelli","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2018.01.001_bib68","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1200\/jco.2014.32.15_suppl.8567","article-title":"Temsirolimus (TEM) and lenalidomide (LEN) in relapsed\/refractory Hodgkin lymphoma including in patients with prior exposure to brentuximab vedotin (BV)","volume":"32","author":"Jasielec","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib69","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib70","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V124.21.806.806","article-title":"Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma","volume":"124","author":"Ruella","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib71","first-page":"1873","article-title":"Anti-CD16\/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines","volume":"7","author":"Hartmann","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.01.001_bib72","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2001-12-0295","article-title":"Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma","volume":"100","author":"Borchmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib73","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1471-2407-13-250","article-title":"Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease\u2014a combined tissue microarray, in\u00a0vitro and in\u00a0vivo study","volume":"13","author":"M\u00e1rk","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2018.01.001_bib74","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A\u00a0phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.01.001_bib75","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bjhh.2017.03.008","article-title":"Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience","volume":"39","author":"Rocha","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.clml.2018.01.001_bib76","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","article-title":"PI3K\u03b4 inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma","volume":"119","author":"Meadows","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib77","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/ijc.21539","article-title":"Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells","volume":"118","author":"Baus","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2018.01.001_bib78","first-page":"549","article-title":"Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells","volume":"60","author":"Joos","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.01.001_bib79","article-title":"The efficacy of JAK2 inhibitor in heavily pretreated classical Hodgkin lymphoma: a prospective pilot study of ruxolitinib in relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"128","author":"Kim","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.001_bib80","doi-asserted-by":"crossref","unstructured":"Horwitz SM, Hamadani M, Fanale MA, et\u00a0al. Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed\/refractory Hodgkin\/non-Hodgkin lymphoma. Presented at the 59th Annual Meeting of the American Society of Hematology, 2017; abstract\u00a01510.","DOI":"10.1002\/hon.2438_143"},{"key":"10.1016\/j.clml.2018.01.001_bib81","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma","volume":"31","author":"Scott","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib82","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","article-title":"Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma","volume":"35","author":"Chan","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clml.2018.01.001_bib83","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hon.2437_80","article-title":"Application of a gene expression-based model in combination with FDG-PET imaging to predict treatment response in advanced Hodgkin lymphoma in the RATHL study (CRUK\/07\/033)","volume":"35","author":"Burton","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clml.2018.01.001_bib84","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hon.2437_81","article-title":"The 23-gene gene expression-based assay does not predict interim PET scan results after ABVD in advanced stage classical Hodgkin lymphoma in the US intergroup S0816 trial","volume":"35","author":"Scott","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib85","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.01.001_bib86","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/annonc\/mdr157","article-title":"Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma","volume":"23","author":"Azambuja","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib87","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1309\/AJCP61TLMXLSLJYS","article-title":"CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma","volume":"141","author":"Klein","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2018.01.001_bib88","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2295","article-title":"Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma","volume":"35","author":"Gotti","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.01.001_bib89","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-13-1879","article-title":"Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma","volume":"19","author":"Marri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.01.001_bib90","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cam4.585","article-title":"CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma","volume":"5","author":"Cuccaro","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2018.01.001_bib91","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1080\/10428190802441339","article-title":"Elevated pretreatment interleukin-10 serum level is an international prognostic score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma","volume":"49","author":"Rautert","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.01.001_bib92","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.14317","article-title":"Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC","volume":"175","author":"Plattel","year":"2016","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017319055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017319055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:06Z","timestamp":1761870606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017319055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S2152265017319055"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.01.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}